A new combination of drugs could help delay the advancement of a deadly form of prostate cancer in those with an advanced form of the disease, new research has found. The “striking” findings showed an ...

ORNL is a leader both in developing advanced radiotherapies and in providing the radioisotopes needed for those therapies.

Nearly three years of research have brought about remarkable results for the majority of 80 patients subjected to targeted alpha therapy of metastatic prostate cancer. The first assessments - ...

Top experts share the latest bladder, kidney and prostate cancer advances from the 2026 ASCO GU Symposium, highlighting patient impact. At the 2026 ASCO GU meeting, experts gathered to share the ...

“This is a rare opportunity for me personally, this is my only hope to extend my life by any real period at all." The post ...

Historically, treatment for metastatic prostate cancer relied heavily on androgen deprivation therapy (ADT) alone. Over time, research has demonstrated that combining ADT with additional agents ...

The Prostate Cancer Foundation (PCF) today announced the recipients of its 2025 Challenge Awards, providing over $12 million in funding for 12 multi-institutional, cross-disciplinary research teams ...

Men with aggressive prostate cancer, often left with few options after chemotherapy fails, now have access to a new treatment that uses a radioactive substance.The new treatment, Lutetium-177 PSMA ...

Former UK prime minister Rishi Sunak has called for a targeted prostate cancer screening program for men most at high risk of the disease, reviving a national debate on how to save more lives and ...

Tagawa, MD, identified 3 primary clinical scenarios where PSMA PET scans have become the established standard for prostate cancer care. The first application is initial s ...

Germline testing can identify hereditary cancer, which leads to implications for family members, cascade testing for relatives, and starting surveillance and prevention measures: Genetic testing in ...